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SUMMARY 
Background: Pemphigus vulgaris (PV) is an autoimmune disease characterized by 
mucocutaneous intraepithelial blisters and pathogenic autoantibodies against desmoglein 
3. The mechanism of blister formation in pemphigus has not been defined; however, in 
vitro data suggest a role for activation of intracellular signalling cascades. 
Objectives: To investigate the contribution of these signalling pathways to the 
mechanism of PV IgG-induced acantholysis in vivo. 
Methods: We used the passive transfer mouse model. Mice were injected with IgG 
fractions of sera from a patient with PV, with or without pretreatment with inhibitors of 
proteins that mediate intracellular signalling cascades. 
Results: Inhibitors of tyrosine kinases, phospholipase C, calmodulin and the 
serine⁄threonine kinase protein kinase C prevented PV IgG-induced acantholysis in vivo. 
Conclusions: These observations strongly support the role of intracellular signalling 
cascades in the molecular mechanism of PV IgG-induced acantholysis. 










Pemphigus vulgaris (PV) is an autoimmune mucocutaneous disease characterized by 
intraepidermal blisters and epidermal-specific autoantibodies.1 These autoanti-bodies are 
pathogenic in passive transfer studies2 and recognize the desmosomal cadherin 
desmoglein (Dsg) 3.3 In approximately 50% of PV patients, a second pathogenic 
autoantibody recognizes Dsg1.4 Dsg1 is also the antigen bound by pemphigus foliaceus 
autoantibodies.5 It appears that the mucosal form of PV is characterized by a 
predominantly anti-Dsg3 autoimmune response, whereas the mucocutaneous form shows 
a combined anti-Dsg3 and anti-Dsg1 autoantibody response.6
The molecular mechanisms leading to PV IgGinduced epidermal cell detachment 
(acantholysis) and blister formation remain under intense investigation in several 
laboratories. The initiation of cell detachment by the binding of PV antibodies to the 
ectodomain of Dsg3 has been demonstrated in vitro;7 this process begins with binding, 
clustering and internalization of the PV-IgG ⁄antigen complexes.8 The observation that 
PV IgG and its Fab and F(ab)2 fragments are also pathogenic in passive transfer studies9 
led to the suggestion that antibody binding to specific epitopes of Dsg3 might sterically 
impair the ability of Dsg3 to function in cell–cell adhesion.10 Recent studies have mapped 
the pathogenic antibody binding sites to epitopes within the EC1 domain of Dsg3.11
A hypothesis supported by recent experimental data proposes that binding of PV 
antibodies to the ectodomain of Dsg3 triggers an intracellular signalling response in 
keratinocytes that leads to acantholysis.12,13 In vitro studies have demonstrated activation 
of the phospholipase C (PLC) pathway following the binding of PV antibodies to target 
antigens.13,14 PLC hydrolyses phosphatidylinositol diphosphate into diacylglycerol (DG) 
and inositol triphosphate (IP3). DG activates the serine ⁄threonine kinase protein kinase C 
(PKC) and IP3 leads to the release of intracellular calcium. Rapid increases in IP3, 
intracellular calcium12 and PKC14,15 have been observed in keratinocyte cultures exposed 
to PV IgG. The PLC inhibitor U-73122 inhibited this response.13 Additionally, the 
binding of PV antibodies to keratinocytes has been associated with increased 
phosphorylation of Dsg3 and the dissociation of the Dsg3-plakoglobin complex, a 
process that may also contribute to the mechanism of acantholysis.16 Intracellular 
signalling induced by PV antibodies has been hypothesized to be linked to the release of 
plasminogen activator (PA) from keratinocytes, which in turn is proposed to lead to the 
degradation of cell–cell contacts;13,17,18 however, the role of PA in PV acantholysis has 
been challenged by studies demonstrating PV autoantibody-induced acantholysis in mice 
depleted of PA.19,20 Interestingly, keratinocytes derived from plakoglobin knockout mice 
are resistant to the pathogenic effect of PV antibodies, suggesting that the linkage of 
desmosomal Dsg3 to the cytoskeleton via plakoglobin might have a central role in the 
molecular events leading to acantholysis.21
We sought to investigate the contribution of these signalling pathways to the mechanism 
of acantholysis in vivo using the passive transfer mouse model. We observed that 
inhibitors of protein tyrosine kinases (TKs), PLC, calmodulin and the serine ⁄threonine 
kinase PKC prevent PV IgG-induced acantholysis in vivo. These observations provide 
strong support for the role of PV IgG-induced activation of signalling cascades in the 
molecular mechanism of acantholysis. 
MATERIALS AND METHODS 
Human sera 
Serum samples were obtained from a patient with mucocutaneous PV, during states of 
both active disease (PV1a) and disease remission (PV1b), and from a normal human 
donor. Patient and control sera were tested by indirect immunofluorescence (IF) using 
monkey oesophagus as a tissue substrate. The immunological characteristics of these sera 
are presented in Table 1. 
  
IgG purification 
IgG fractions of sera from the patient with PV and the normal human donor were 
prepared as previously described.2,22 Briefly, IgG fractions were precipitated with 50% 
ammonium sulphate followed by affinity chromatography on Staphylococcus protein A 
conju-gated to agarose beads. Bound IgG was eluted with 0.2 mol L-1 glycine⁄HCl, pH 3, 
dialysed extensively against phosphate-buffered saline (PBS), pH 7·4, concentrated by 
ultrafiltration (Millipore⁄Amicon, Beverly, MA, U.S.A.), filter-sterilized, and stored at -
70 °C until use. Protein concentrations were determined by Bradford assay.23 The IgG 
concentration in each fraction was estimated by nephelometry using goat antihuman IgG 
(Beckman Array 360 System, Holliston, MA, USA). 
 
Detection of antidesmoglein 3 antibodies by immunoprecipitation 
The anti-Dsg3 activity of the PV patient sera was assayed by immunoprecipitation (IP) of 
recombinant Dsg3 (rDsg3).4 Three microlitres of each serum were incubated with 3 µg of 
rDsg3 for 1 h at room temperature followed by addition of protein A-conjugated agarose 
beads, and subjected to extensive washing with 0.1% Triton X-100 in Tris-buffered saline 
containing 3 mmol L-1 of calcium prior to elution of the immunoprecipitates from the 
beads with Laemmli sample buffer [2% sodium dodecyl sulphate (SDS), 0.1 mol L-1 Tris, 
pH 6.8]. Immunoprecipitates were separated by 10% SDS–polyacrylamide gel 
electrophoresis, transferred to nitrocellulose membrane, and probed by Western blot 
analysis using rabbit antihuman Dsg3 primary antibodies (1:2000) and horseradish 
peroxidase-conjugated goat antirabbit IgG secondary antibodies (1:3000). The 
immunoreactants were developed using the enhanced chemiluminescence reaction (ECL-
Plus system; Amersham Pharmacia Biotech, St Albans, U.K.). 
 Detection of antidesmoglein 3 antibodies by enzyme-linked immunosorbent assay 
PV sera were tested by two enzyme-linked immunosorbent assay (ELISA) techniques. In 
the first, recombinant histidine-tagged Dsg3 protein encompassing the ectodomain of 
Dsg3 was expressed in baculovirus4 and afinity-purfied by Ni-agarose chromatography. 
Microtitre Ni-coated plates were incubated with 1 µg per well of rDsg3, blocked with 
0.2% bovine serum albumin, washed extensively with 0.5% Tween 20 in Tris buffer, pH 
7.3, and used to test the patient and control sera for the presence of antiDsg3 reactivity in 
ELISA.24 The second protocol utilized a commercially available ELISA kit to test for 
anti-Dsg3 antibodies according to the manufacturer’s recommendations (RhiGene Inc., 
Des Plaines, IL, U.S.A.). The ELISA results are given in arbitrary units as follows: 
negative (£ 9 units), indeterminate (10–20 units) and positive for anti-Dsg3 (> 20 units). 
The results obtained from both ELISA techniques were comparable; data are shown for 
the more readily available commercial kit. 
 
Testing of IgG pathogenicity using the passive transfer animal model 
Each IgG fraction was tested for pathogenicity by passive transfer experiments as 
previously described.2,22 IgG from PV1a and PV1b sera was injected intradermally (4 mg 
g-1 body weight) into neonatal Balb ⁄C mice (n = 3 for each IgG) and evaluated 24 h later 
for evidence of skin blisters. Following examination of the skin for blisters, animals were 
killed, and serum was collected for indirect IF assays, using human skin as substrate. Skin 
biopsies from each animal included lesional skin samples for routine histological 
examination by haematoxylin and eosin staining and perilesional skin for direct IF 
studies. 
 
Investigation of the role of inhibitors of signalling pathways on pemphigus vulgaris 
IgG-induced skin disease in mice 
Inhibitors of proteins that mediate intracellular signalling cascades were tested for their 
ability to prevent PV IgG-induced blistering in the passive transfer mouse model. 
Nontoxic doses of the inhibitors genistein (Sigma, St Louis, MO, U.S.A.), herbimycin 
(Sigma), U-73122 (Biomol, Plymouth Meeting, PA, U.S.A.), bisindolylmaleinamide 
(Boehringer Mannheim, Mannheim, Germany) and W-7 hydrochloride (Calbiochem, La 
Jolla, CA, U.S.A.) were selected based on in vitro studies reported elsewhere.14,18 
Additionally, lethality studies carried out in our laboratory demonstrated no increased 
mortality in the mice at 48 h postinjection at inhibitor doses used in this study (data not 
shown). Inhibitors were administered by intradermal injection 3 h before intradermal 
injection of PV IgG. Inhibitors were diluted in PBS and injected into mice (n = 3 for each 
inhibitor) at the following doses: the TK inhibitor genistein, 500 µg g-1 body weight; the 
TK inhibitor herbimycin, 15 µg g-1 body weight; the PLC inhibitor U-73122, 100 µg g-1 
body weight; the PKC inhibitor bisindolylmaleinamide, 100 µg g-1 body weight; and the 
calmodulin antagonist W-7 hydrochloride, 200 µg g-1 body weight. 
 
RESULTS 
PV1a IgG recognizes desmoglein 3 and induces acantholysis in vivo by passive 
transfer to neonatal mice 
The IgG fraction from the patient with PV during the active phase of the disease (PV1a) 
was immunologically characterized for its ability to target Dsg3 specifically. Indirect IF, 
IP and ELISA assays using rDsg3 were used to assay for the presence and titre of Dsg3- 
speciic IgG in each serum sample. Sera from the PV patient, but not from the normal 
human control, recognized rDsg3 (Table 1, Fig. 1). 
Passive transfer experiments in neonatal mice were used to assay for the ability of each 
IgG sample to induce acantholysis in vivo. IgG from normal human serum failed to 
induce acantholysis by passive transfer studies in neonatal mice using two different doses 
of IgG (4 and 8 mg g-1 body weight) (Table 2). In contrast, IgG from PV1a (active 
disease) was pathogenic at 4 mg g-1 body weight; IgG collected from the same patient 
during disease remission (PV1b) was not pathogenic (Table 2, Fig. 2). 
  
Pretreatment of mice with inhibitors of intracellular signalling pathways blocks the 
pathogenic effect of PV1a IgG 
As shown in Table 2 and Figure 2, the pathogenic PV1a IgG failed to induce acantholysis 
in mice pretreated with the TK inhibitor genistein, the TK inhibitor herbimycin, the PLC 
inhibitor U-73122, the PKC inhibitor bisindolylmaleinamide or the calmodulin antagonist 
W-7 hydrochloride. Control mice pretreated with PBS followed by PV1a developed 
extensive disease similar to animals injected with only PV1a IgG. 
   
DISCUSSION 
Pretreatment of mice with inhibitors of intracellular signalling cascades prevented PV 
IgG-induced blister formation in vivo. PV1a IgG was selected to conduct these studies 
because it induced obvious and reproducible disease in neonatal mice and sufficient 
quantities of this serum could be obtained to perform the necessary experiments and 
controls in triplicate. In addition to anti-Dsg3 antibodies, approximately 50% of PV 
patient sera contain a second pathogenic autoantibody that recognizes Dsg1.4 Although 
we have characterized the Dsg3 autoantibodies in the PV1a serum, we have not excluded 
the presence in this serum of Dsg1 autoanti-bodies. On the basis of the generated data, we 
cannot formally determine whether the observed inhibition of blister formation occurred 
via inhibition of anti-Dsg1 and⁄or anti-Dsg3 antibody-mediated acantholysis; however, 
both Dsg1- and Dsg3-specific autoantibodies affinity-purified from human sera are each, 
by them-selves, capable of inducing acantholysis in the passive transfer mouse model.6 
As such, it is not necessary to invoke the presence of Dsg1-specific autoantibodies in the 
mucocutaneous PV1a serum as being necessary for acantholysis in the passive transfer 
mouse model. 
Blisters did not develop when mice were pretreated with the TK inhibitors genistein and 
herbimycin, the PLC inhibitor U-73122, the calmodulin inhibitor W-7, or the PKC 
inhibitor bisindolylmaleinamide. Inhibitorand noninhibitor-treated mice demonstrated 
comparable serum levels of IgG by indirect IF, indicating that pretreatment with 
inhibitors did not impair the entry of IgG from the site of injection into the systemic 
circulation. Additionally, the inhibitors did not affect the ability of pathogenic PV IgG to 
bind to murine epidermis. Direct IF of skin biopsies from mice pretreated with inhibitors 
prior to injection of pathogenic IgG was similar to that of mice that had not been 
pretreated; both groups demonstrated IgG staining at the keratinocyte cell membrane. In 
contrast, inhibitorpretreated mice did not demonstrate acantholysis, indicating that the 
effect of the inhibitors in inhibiting blister formation was downstream of the binding of 
pathogenic IgG to the keratinocyte cell surface. 
The molecular mechanisms of acantholysis have yet to be defined; however, an 
increasing body of data suggests that propagation of signals initiated across the cell 
membrane may have a role in PV IgG-mediated acantholysis.25 Our finding that several 
inhibitors of intracellular signalling cascades inhibit PV IgG acan-tholysis, whether or not 
the PV serum is composed of only anti-Dsg3 autoantibodies or both anti-Dsg3 and anti-
Dsg1 autoantibodies, is consistent with a mechanism in which signalling events 
contribute to the loss of cell–cell adhesion. These inhibitors may, in fact, define specific 
steps in the propagation of PV IgGinitiated signalling. Ligand⁄receptor interactions trigger 
TK activity leading to PLC activation, which in turn activates the phosphatidylinositol-
4,5-diphosphate pathway26 leading to generation of IP3 and DG. Subsequent increases in 
intracellular calcium activate calmodulin and then serine ⁄threonine kinases such as PKC 
and the CAM kinases. The TK inhibitors genistein and herbimycin may inhibit 
acantholysis by disrupting upstream elements of this signalling cascade. Similarly, it is 
not surprising that inhibition of downstream elements, including PLC, calmodulin and 
PKC by U-73122, W-7 and bisindolylmaleinamide, respectively, also inhibits 
acantholysis. Taken together, these data support the role of this signalling cascade in the 
development of PV IgG-induced acantholysis. 
The present studies show that in vivo administration of U-73122 prevents the 
development of acantholysis, confirming the in vitro findings made by others.13 Although 
different isoforms of PLC are inhibited by U-73122, inhibition by genistein and 
herbimycin suggests a role for PLCy in mediating PV IgG signalling. The PKC inhibitor 
bisindolylmaleinamide has been shown to alter the assembly⁄disassembly of the 
desmosomes,26–28 possibly due to changes in phosphorylation of proteins such as 
desmoplakin,29,30 plakoglobin or Dsg3.16
In conclusion, the data demonstrate a role for intracellular signal transduction cascades in 
the devel-opment of PV IgG-induced loss of cell–cell adhesion. In vivo inhibition of 
acantholysis in the mouse model of PV by inhibition of intracellular signalling 
demonstrates the value of targeting these pathways for the treatment of PV in humans. 
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Table 1. Characteristics of IgG fractions 
Sera Indirect IF titre (MO) IP (rDsg3) ELISA (rDsg3) 
PV1a 1 : 80 Positive Not done 
PV1b Negative Not done 39 units 
Normal human serum Negative Negative Negative 
IF, immunofluorescence; MO, monkey oesophagus; IP, immunoprecipitation; 
rDsg3, recombinant desmoglein 3; ELISA, enzyme-linked immunosorbent assay;      




Table 2. Testing pathogenic PV1 IgG by passive transfer in mice 













Normal IgG 3 Absent Normal Negative Negative 
PV1a IgG 3 + + + Acantholysis + + + 1 : 40 
PV1b IgG 3 Absent Normal Negative Negative 
PV1a IgG + PBS 3 + + + Acantholysis + + + 1 : 80 
PV1a IgG + genistein 3 Absent Normal + + + 1 : 40 
PV1a IgG + herbimycin 3 Absent Normal + + + 1 : 20 to 
1 : 80 
PV1a IgG + 
bisindolylmaleinamide 
3 Absent Normal + + + 1 : 40 to 
1 : 80 
PV1a IgG + U-73122 3 Absent Normal + + + 1 : 80 
PV1a IgG + W-7 3 Absent Normal + + + 1 : 20 to 
1 : 40 








Figure 1. Detection of antidesmoglein (antiDsg) 3 autoantibodies by 
immunoprecipitation of recombinant Dsg3 (rDsg3). rDsg3 is shown in lane 1. A 
negative control serum (lane 2), a positive control pemphigus vulgaris (PV) serum (lane 
3) and the PV1 test serum (lane 4) were incubated with rDsg3 and precipitated with 
protein A-agarose beads. The immunoprecipitates were fractionated by 10% sodium 
dodecyl sulphate–polyacrylamide gel electrophoresis and blotted to nitrocellulose. To 
detect precipitated rDsg3, the blots were probed with rabbit anti-Dsg3 primary 
antibodies, goat antirabbit IgG horseradish peroxidase-conjugated secondary antibodies, 
and developed by enhanced chemiluminescence. The 66-kDa ectodomain of rDsg3 is 



















Figure 2. Inhibition of intracellular signalling cascades prevents pemphigus vulgaris 
(PV) IgG blister formation in vivo. The clinical, histological and immunofluorescent 
characteristics of neonatal mice injected with PV IgG (PV1a) were compared with those 
in mice pretreated with the tyrosine kinase inhibitor herbimycin prior to injection of 
pathogenic PV IgG (PV1a + herbimycin). Gross blister formation and histological 
acantholysis are seen in the PV-treated mice. Pretreatment with herbimycin prevents 
both gross and histological evidence of blister formation (black ink marks the PV serum 
injection site). Direct immunofluorescence staining of punch biopsies demonstrates cell 
surface staining for PV IgG in both PV IgG- and PV IgG + herbimycin-treated mice, 
demonstrating that pretreatment with herbimycin did not affect the in vivo desmoglein 3 
binding of the pathogenic IgG. Similar results to that observed in the herbimycin-
pretreated mice were obtained in mice pretreated with genistein, U-73122, 
bisindolylmaleinamide and W-7 hydrochloride. 
